This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens and for the manufacture of a medicament for the treatment of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.Spoj FGF-18 za uporabu kod liječenja poremećaja hrskavice naznačen time da se spoj FGF-18 daje tijekom barem 3 uzastopna tjedna po ciklusu terapije, te su navedena davanja odvojena sa oko najmanje 6, 7 ili 8 dana. Patent sadrži još 14 patentnih zahtjeva.
